{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:52:41Z","timestamp":1781927561009,"version":"3.54.5"},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7096-26","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:10:09Z","timestamp":1781734209000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment and burden of patients with chronic myeloid leukemia in Japan: A retrospective claims database analysis"],"prefix":"10.2169","author":[{"given":"Eri","family":"Matsuki","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Leboucher","sequence":"additional","affiliation":[{"name":"RWE & Biostatistics, Putnam, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salsabil","family":"Touzenil","sequence":"additional","affiliation":[{"name":"RWE & Biostatistics, Putnam, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Qu\u00e9len","sequence":"additional","affiliation":[{"name":"RWE & Biostatistics, Putnam, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Chung","sequence":"additional","affiliation":[{"name":"Medical Affairs Division, Novartis Pharma K.K, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ning L, Hu C, Lu P, Que Y, Zhu X, Li D. Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study. Exp Hematol Oncol 9 (1): 29, 2020.","DOI":"10.1186\/s40164-020-00185-z"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. H\u00f6glund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 94 (Suppl 2): S241-S247, 2015.","DOI":"10.1007\/s00277-015-2314-2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chihara D, Ito H, Matsuda T, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164 (4): 536-545, 2014.","DOI":"10.1111\/bjh.12659"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol 95 (6): 691-709, 2020.","DOI":"10.1002\/ajh.25792"},{"key":"5","unstructured":"5. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8 (5): 935-942, 2002."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (11): 994-1004, 2003.","DOI":"10.1056\/NEJMoa022457"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Waller CF. Imatinib Mesylate. Recent Results Cancer Res 212: 1-27, 2018.","DOI":"10.1007\/978-3-319-91439-8_1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Al-Ali HK, Heinrich MC, Lange T, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 5 (1): 55-60, 2004.","DOI":"10.1038\/sj.thj.6200319"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 (2): 690-698, 2003.","DOI":"10.1182\/blood.V101.2.690"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (5682): 399-401, 2004.","DOI":"10.1126\/science.1099480"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2): 129-141, 2005.","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34 (4): 966-984, 2020.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Shimoda K, Takahashi N, Kirito K, Iriyama N, Kawaguchi T, Kizaki M. JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol 112 (3): 268-291, 2020.","DOI":"10.1007\/s12185-020-02964-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yeung DT, Shanmuganathan N, Hughes TP. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. Blood 139 (24): 3474-3479, 2022.","DOI":"10.1182\/blood.2021014689"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hochhaus A, Wang J, Kim DW, et al. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med 391 (10): 885-898, 2024.","DOI":"10.1056\/NEJMoa2400858"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Morita K, Sasaki K. Current status and novel strategy of CML. Int J Hematol 113 (5): 624-631, 2021.","DOI":"10.1007\/s12185-021-03127-5"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103 (7): 553-561, 2011.","DOI":"10.1093\/jnci\/djr060"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol 34 (24): 2851-2857, 2016.","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gunnarsson N, Sandin F, H\u00f6glund M, et al. Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence. Eur J Haematol 97 (4): 387-392, 2016.","DOI":"10.1111\/ejh.12743"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Quint\u00e1s-Cardama A, Cort\u00e9s JE, Kantarjian H. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma 8 (Suppl 3): S82-S88, 2008.","DOI":"10.3816\/CLM.2008.s.003"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Gu\u00e9rin A, Chen L, Ionescu-Ittu R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin 30 (11): 2317-2328, 2014.","DOI":"10.1185\/03007995.2014.944973"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Eliasson L. Treatment adherence in chronic myeloid leukemia: A systematic review of the literature. Clinical Practice 9 (1): 87-101, 2012.","DOI":"10.2217\/cpr.11.127"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Geissler J, Sharf G, Bombaci F, et al. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol 143 (7): 1167-1176, 2017.","DOI":"10.1007\/s00432-017-2372-z"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of clinical oncology 28 (14): 2381, 2010.","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Gu\u00e9rin A, Wu EQ, Bollu VK, et al. The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Journal of medical economics 16 (1): 125-133, 2013.","DOI":"10.3111\/13696998.2012.693896"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Bouwmans C, Janssen J, Huijgens P, Uyl-de Groot C. Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia. J Med Econ 12 (2): 164-169, 2009.","DOI":"10.3111\/13696990903149479"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Nakamura M. 1. Utilization of MDV Data and Data Quality Control. Japanese Journal of Pharmacoepidemiology 21 (1): 23-25, 2016.","DOI":"10.3820\/jjpe.21.23"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19 (6): 747-757, 2018.","DOI":"10.1016\/S1470-2045(18)30192-X"},{"key":"29","unstructured":"29. Mahon FX, Pfirrmann M, Dulucq S, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. J Clin Oncol 42 (16): 1875-1880, 2024."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol 94 (3): 346-357, 2019.","DOI":"10.1002\/ajh.25342"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Breccia M, Chiodi F, Nardozza AP, et al. The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy. Adv Ther 40 (3): 961-974, 2023.","DOI":"10.1007\/s12325-022-02398-6"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7096-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:37:44Z","timestamp":1781926664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7096-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":31,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7096-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7096-26"}}